Latvia vs Slovakia: Life science patents granted, by technology
Latvia
4 patents
in 2023
Slovakia
3 patents
in 2023
Latvia rank
45th
Slovakia rank
48th
Life science patents granted, by technology over time
- Latvia
- Slovakia
How they compare
Latvia currently reports 4 patents against 3 patents in Slovakia, a difference of 1 patents.
That makes Latvia's figure about 1.3 times Slovakia's.
The two have swapped places 4 times across 28 shared years of data; in 1994 it was Latvia ahead.
Latvia ranks 45th and Slovakia ranks 48th of 65 countries.
Across the 4 decades both report, Latvia averaged higher in 1 and Slovakia in 2.
Head to head by decade
| Decade | Latvia | Slovakia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 71.33 patents | 49.5 patents | 21.83 patents | Latvia |
| 2000s | 14.7 patents | 134.8 patents | 120.1 patents | Slovakia |
| 2010s | 7.5 patents | 29.5 patents | 22 patents | Slovakia |
| 2020s | 2.5 patents | 2.5 patents | 0 patents | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher life science patents granted, by technology, Latvia or Slovakia?
- Latvia, at 4 patents against 3 patents in Slovakia as of 2023.
- What is the difference in life science patents granted, by technology between Latvia and Slovakia?
- 1 patents, with Latvia ahead.
- How many years of comparable data are there for Latvia and Slovakia?
- 28 years are reported by both, from 1994 to 2023.
- How do Latvia and Slovakia rank globally for life science patents granted, by technology?
- Latvia ranks 45th and Slovakia ranks 48th of 65 countries.
- Where does this data come from?
- World Intellectual Property Organization (WIPO) (2025) – processed by Our World in Data, published as Life science patents granted, by technology. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of pharmaceutical patents granted by the filing office in a given year. Pharmaceutical patents typically cover new drugs, biological treatments or vaccines.